Medtronic Plc

MDT · NYSE · USD

Can cardiac ablation, Symplicity, Altaviva and Hugo keep Medtronic's growth accelerating once the ablation comparisons get harder?

Last 4 earnings calls · through Q1 FY2027

Bull case

  • Cardiac ablation share gains

    The bull case is that Medtronic's ablation platform keeps winning share in electrophysiology, and every system placed pulls through years of higher-margin catheter sales.

  • Broadening growth drivers

    Management argues that Symplicity, Altaviva, Hugo and Stealth AXiS are moving from launch to commercial scale and can add growth on top of the base business.

  • Guidance raised

    Each quarter of the past year has brought a higher full-year revenue outlook, which the bulls read as evidence that the acceleration is being planned rather than promised.

Bear case

  • Harder ablation comparisons

    The bear case is that cardiac ablation sits inside a very large company, so its growth rate must fall as it laps its own launch and stops adding as much to the total.

  • Structural Heart decline

    The bears point out that the TAVR franchise went from a reliable grower to flat after weaker long-term clinical data, and they doubt new investments fix it quickly.

  • Tariffs and product mix

    They also argue that tariffs, acquisition dilution and a lower-margin product mix will keep profit growth from matching the revenue improvement management is promising.

Bull and bear points

Growth & Execution

In short: Growth is accelerating across several units, but its fastest-growing piece is guided to slow.

Bull · 3

  • Cardiac ablation passed $2 billion in trailing revenue ahead of schedule

    Hitting the target early shows the Affera rollout is producing revenue, not just placements, and this year's installed base supports years of higher-margin catheter sales.

    Q1 FY2027 call

  • Cardiac rhythm, spine technology and surgical units all grew

    Growth no longer rests on one product line: CRM, spine technology and surgical instruments all contributed, so the total rate depends less on a single launch.

    Q1 FY2027 call

  • Full-year revenue guidance was raised after one quarter

    A quarter ago the company guided fiscal 2027 organic growth to 6.75% to 7.25%; after one quarter it lifted that range to 7.25% to 7.75%, citing broad demand and the extra selling week.

    Tone shiftQ4 FY2026 → Q1 FY2027
Bear · 2

  • Ablation growth is guided to slow through the rest of the year

    Management expects cardiac ablation to keep outpacing the electrophysiology market this year but at a moderating rate as prior-year comparisons strengthen, so it adds less incremental growth each quarter.

    Q1 FY2027 call

  • Structural Heart went from growing to flat within three quarters

    Earlier management credited the Evolut valve platform for growth in Structural Heart; now the unit is flat with a softer U.S., and management only says weekly procedure volumes have stabilized.

    Tone shiftQ2 FY2026 → Q4 FY2026

Profitability & Financial Strength

In short: Cash generation is strong, while tariffs and product mix still hold back gross margin.

Bull · 2

  • Free cash flow reached $6.1 billion, above the prior year

    Free cash flow rose from $5.3 billion a year earlier, giving management room to fund acquisitions, the dividend and buybacks without leaning on debt.

    Filed financials

  • Separating MiniMed lifts gross margin about 50 basis points

    Diabetes carries a structurally lower margin and roughly twice the research spending intensity of the rest of Medtronic, so removing it raises reported margins and frees capital for higher-return segments.

    Q1 FY2027 call
Bear · 2

  • Tariff cost estimate rose to $250 million from $185 million

    A year ago the company put tariffs at $185 million; the fiscal 2027 plan now carries $250 million and assumes no refunds, so tariff relief is upside rather than a base case.

    Tone shiftQ2 FY2026 → Q4 FY2026

  • Product mix keeps gross margin from expanding

    Selling lower-margin ablation capital equipment ahead of catheters, plus the diabetes business, held gross margin down in recent quarters, and management expects that effect to shrink only gradually.

    Q4 FY2026 call

Market Position

In short: Medtronic leads in cardiac rhythm and spine, while heart valve competition pressures Structural Heart.

Bull · 2

  • Medicare coverage decision for Symplicity is broad and final

    A national coverage determination sets payment rules for renal denervation nationwide, and the final version removed patient pathway restrictions, which helps hospitals justify starting programs.

    Q2 FY2026 call

  • Conduction system pacing extends the cardiac rhythm lead

    Hospitals adopting pacing leads that work with the heart's conduction system are choosing Medtronic, and that installed base drives recurring replacement procedures competitors must dislodge patient by patient.

    Q1 FY2027 call
Bear · 2

  • China volume-based procurement keeps pressuring device prices

    Tenders in China force price concessions across several Medtronic product lines, and management now treats the mechanism as permanent, so growth there depends on volume and cost cuts rather than price.

    10-K, filed 2026-06-18

  • Hugo enters soft-tissue robotics as a challenger, not the leader

    Robotic surgery is led by an entrenched competitor, and Medtronic describes its own goal as becoming a meaningful second player, so hospital adoption and pricing are set largely by the incumbent.

    Q1 FY2027 call